This trial is testing a new drug, ARO-ANG3, to see if it is effective and safe in treating mixed dyslipidemia. Participants will receive injections of either the drug or a placebo, and then may continue receiving the drug in an extension of the trial.
1 Primary · 18 Secondary · Reporting Duration: Baseline, up to Week 36 (double-blind treatment period), up to Month 24 (open-label extension)
204 Total Participants · 2 Treatment Groups
Primary Treatment: ARO-ANG3 · Has Placebo Group · Phase 2
Age 18+ · All Participants · 9 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
|18 - 65||100.0%|
|Did not meet criteria||100.0%|